Join
Search

Posts Tagged ‘corporate influence’

New Allegations of Political and Corporate Pressure on FDA

In today’s New York Times, Gardiner Harris describes tensions between the FDA, Congress and the White House regarding the agency’s attempts to inform and protect the public. It’s an incredible article that helps demonstrate the pervasiveness of both political and corporate pressure on the agency, and how those who do not have scientific training in public health attempt to take decision-making authority on what should be scientific issues away from those who do.

Read More

Bookmark and Share

GM Drives Away From Climate Denial, Dumps Heartland Institute

The big news today is that General Motors said they’ll no longer fund a group that regularly attacks climate science.

According to the Huffington Post, “The automaker told the Heartland Institute last week that it won’t be making further donations, spokesman Greg Martin said.” Read More

Bookmark and Share

Money Talks, and What It’s Saying May Harm the FDA

Any way you look at it, $700 million is a lot of cash. That’s the amount that industries regulated by the FDA have spent since 2009 lobbying Congress and the Executive Branch. That investment is paying off as Congress now considers must-pass legislation that governs how the FDA uses science to evaluate prescription drugs and medical devices. Read More

Bookmark and Share

Five Reasons Congress Should Support Strong Conflict-of-Interest Standards at FDA

As I’m sure you’ve noticed, we have been blogging quite a bit recently about the FDA. This corresponds to legislation that would determine how the FDA approves and monitors drugs and medical devices. But why have we been so focused on reducing the number of FDA advisory panel members who have financial conflicts-of-interest? Read More

Bookmark and Share

Vioxx shows what happens when the drug safety system breaks down

In a previous blog post, I explained the FDA’s complex process for approving drugs and medical devices. However, in many cases, pressure from commercial interests has broken down this process. The approval and subsequent recall of Vioxx took its toll on thousands of Americans, including my own father.

Read More

Bookmark and Share

How the FDA Drug Approval Process Works

Earlier this week, my colleague Michael gave some general background on the Food and Drug Administration and what Congress has to do this year to ensure that the agency can continue to ensure the safety and efficacy of prescription drugs and medical devices. Read More

Bookmark and Share

For Drugs and Medical Devices, It’s Still a Jungle Out There

When UCS started looking at the use of science at the FDA several years ago, I sat down and read The Jungle, which has been credited with prompting President Theodore Roosevelt to establish the first iteration of the Food and Drug Administration more than a century ago. The grisly descriptions of the Chicago meat-packing industry still conjure up vivid images in my mind.

We’ve made great strides over the past century in protecting the public from unsafe food products. But it’s an entirely different part of the FDA’s wheelhouse that will be taking center stage over the next two months: the regulation of prescription drugs and medical devices. Read More

Bookmark and Share

The EPA Follows Through on Dioxin

February brought two significant pieces of good news at the EPA. The agency released its final scientific integrity policy, which was much improved over the draft it put out for public comment. And the EPA finally released a scientific assessment of dioxin, an achievement 27 years in the making. Read More

Bookmark and Share

On Toxic Dioxin, Will the EPA Fold or Stand Tall?

In August 2011, the Environmental Protection Agency committed to releasing a scientific assessment of the health hazards of chemical dioxins by the end of January 2012. The assessment process has dragged on for nearly three decades—and consistent with what has now become a pattern, the industries that are most responsible for dioxin releases are pushing for yet another delay. Read More

Bookmark and Share